63 results
ARS
2023 FY
XFOR
X4 Pharmaceuticals Inc
29 Apr 24
Annual report to shareholders
4:58pm
and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer … a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee
8-K
EX-10.1
fl2wvtw6b1fx99 br
16 May 23
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
4:24pm
8-K
EX-1.1
q0r5sgoh
9 Dec 22
X4 Pharmaceuticals Announces Proposed Public Offering
8:46am
424B5
xs3lrusx oxa
8 Dec 22
Prospectus supplement for primary offering
5:47pm
424B5
01h2b3ewmazvvzls
6 Dec 22
Prospectus supplement for primary offering
9:52pm
8-K
EX-10.1
ovbf0wjhmcn9
1 Jul 22
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
4:34pm
8-K
EX-10.1
ru9u1vb eclo13azi
3 Mar 22
Entry into a Material Definitive Agreement
4:18pm
424B5
oupu4tdo8milxazp8j
14 Jan 22
Prospectus supplement for primary offering
4:37pm
8-K
EX-10.1
0z6vvry sbfc522cnto
5 Nov 21
Entry into a Material Definitive Agreement
5:27pm